Cat. No.: HY-B0886A

Iproniazid

2 Cited Publications

Customer Review

Based on 2 publication(s) in Google Scholar

Iproniazid is an orally active, irreversible, non-selective monoamine oxidase (MAO) inhibitor. Iproniazid inhibits MAO activity and enhances Rotenone (HY-B1756)-induced Apoptosis. Iproniazid modulates neurotransmitter levels, affects neuronal function, induces hepatic necrosis, and interferes with the endocrine system. Iproniazid can be used in the research of depression, Parkinson's disease, and hepatotoxicity.

For research use only. We do not sell to patients.

Purity: 99.91%
CAS No.: 54-92-2
Formula: C₉H₁₃N₃O
Molecular Weight:179.22

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Iproniazid Chemical Structure

CAS No.: 54-92-2

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (2)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

All Monoamine Oxidase Isoforms :

MAO-A
MAO-B

Cellular Effect

Cell Line	Type	Value	Description	References
BTI-TN-5B1-4	IC₅₀	6.56 μM Compound: iproniazide	Inhibition of human recombinant MAOA expressed in BTI-TN-5B1-4 cells assessed as effect on H2O2 production from para-tyramine by fluorimetric method Inhibition of human recombinant MAOA expressed in BTI-TN-5B1-4 cells assessed as effect on H2O2 production from para-tyramine by fluorimetric method	[PMID: 19267475]
BTI-TN-5B1-4	IC₅₀	7.54 μM Compound: iproniazide	Inhibition of human recombinant MAOB expressed in BTI-TN-5B1-4 cells assessed as effect on H2O2 production from para-tyramine by fluorimetric method Inhibition of human recombinant MAOB expressed in BTI-TN-5B1-4 cells assessed as effect on H2O2 production from para-tyramine by fluorimetric method	[PMID: 19267475]
BTI-TN-5B1-4	IC₅₀	6.56 μM Compound: Iproniazid	Inhibition of human recombinant MAOA expressed in BTI-TN-5B1-4 cells by para-tyramine oxidation assay Inhibition of human recombinant MAOA expressed in BTI-TN-5B1-4 cells by para-tyramine oxidation assay	[PMID: 20045650]
BTI-TN-5B1-4	IC₅₀	7.54 μM Compound: Iproniazid	Inhibition of human recombinant MAOB expressed in BTI-TN-5B1-4 cells by para-tyramine oxidation assay Inhibition of human recombinant MAOB expressed in BTI-TN-5B1-4 cells by para-tyramine oxidation assay	[PMID: 20045650]
BTI-TN-5B1-4	IC₅₀	6566 nM Compound: iproniazid	Inhibition of human recombinant MAOA expressed in baculovirus infected BTI-TN-5B1-4 insect cells assessed as hydrogen peroxide production from p-tyramine by amplex red assay Inhibition of human recombinant MAOA expressed in baculovirus infected BTI-TN-5B1-4 insect cells assessed as hydrogen peroxide production from p-tyramine by amplex red assay	[PMID: 20579890]
BTI-TN-5B1-4	IC₅₀	7547 nM Compound: iproniazid	Inhibition of human recombinant MAOB expressed in baculovirus infected BTI-TN-5B1-4 insect cells assessed as hydrogen peroxide production from p-tyramine by amplex red assay Inhibition of human recombinant MAOB expressed in baculovirus infected BTI-TN-5B1-4 insect cells assessed as hydrogen peroxide production from p-tyramine by amplex red assay	[PMID: 20579890]
BTI-TN-5B1-4	IC₅₀	6.56 μM Compound: iproniazid	Inhibition of human recombinant MAOA expressed in baculovirus infected insect BTI-TN-5B1-4 cells assessed as production of hydrogen peroxide from p-tyramine by amplex red assay Inhibition of human recombinant MAOA expressed in baculovirus infected insect BTI-TN-5B1-4 cells assessed as production of hydrogen peroxide from p-tyramine by amplex red assay	[PMID: 20715818]
BTI-TN-5B1-4	IC₅₀	7.54 μM Compound: iproniazid	Inhibition of human recombinant MAOB expressed in baculovirus infected insect BTI-TN-5B1-4 cells assessed as production of hydrogen peroxide from p-tyramine by amplex red assay Inhibition of human recombinant MAOB expressed in baculovirus infected insect BTI-TN-5B1-4 cells assessed as production of hydrogen peroxide from p-tyramine by amplex red assay	[PMID: 20715818]
BTI-TN-5B1-4	IC₅₀	6.56 μM Compound: Iproniazide	Inhibition of human recombinant MAO-A expressed in BTI-TN-5B1-4 cells assessed as H2O2 production using para-tyramine substrate by fluorimetric method Inhibition of human recombinant MAO-A expressed in BTI-TN-5B1-4 cells assessed as H2O2 production using para-tyramine substrate by fluorimetric method	[PMID: 21316817]
BTI-TN-5B1-4	IC₅₀	7.54 μM Compound: Iproniazide	Inhibition of human recombinant MAO-B expressed in BTI-TN-5B1-4 cells assessed as H2O2 production using para-tyramine substrate by fluorimetric method Inhibition of human recombinant MAO-B expressed in BTI-TN-5B1-4 cells assessed as H2O2 production using para-tyramine substrate by fluorimetric method	[PMID: 21316817]
BTI-TN-5B1-4	IC₅₀	6.56 μM Compound: Iproniazid	Inhibition of human recombinant MAO-A expressed in baculovirus infected BTI-TN-5B1-4 insect sells assessed as hydrogen peroxide production by fluorimetric method Inhibition of human recombinant MAO-A expressed in baculovirus infected BTI-TN-5B1-4 insect sells assessed as hydrogen peroxide production by fluorimetric method	[PMID: 21405131]
BTI-TN-5B1-4	IC₅₀	7.54 μM Compound: Iproniazid	Inhibition of human recombinant MAO-B expressed in baculovirus infected BTI-TN-5B1-4 insect sells assessed as hydrogen peroxide production by fluorimetric method Inhibition of human recombinant MAO-B expressed in baculovirus infected BTI-TN-5B1-4 insect sells assessed as hydrogen peroxide production by fluorimetric method	[PMID: 21405131]
BTI-TN-5B1-4	IC₅₀	6.56 μM Compound: Iproniazid	Inhibition of human recombinant MAO-A expressed in baculovirus infected BTI-TN-5B1-4 cells assessed as production of hydrogen peroxide from p-tyramine after 15 mins by microplate fluorescence assay Inhibition of human recombinant MAO-A expressed in baculovirus infected BTI-TN-5B1-4 cells assessed as production of hydrogen peroxide from p-tyramine after 15 mins by microplate fluorescence assay	[PMID: 21872365]
BTI-TN-5B1-4	IC₅₀	7.54 μM Compound: Iproniazid	Inhibition of human recombinant MAO-B expressed in baculovirus infected BTI-TN-5B1-4 cells assessed as production of hydrogen peroxide from p-tyramine after 15 mins by microplate fluorescence assay Inhibition of human recombinant MAO-B expressed in baculovirus infected BTI-TN-5B1-4 cells assessed as production of hydrogen peroxide from p-tyramine after 15 mins by microplate fluorescence assay	[PMID: 21872365]
BTI-TN-5B1-4	IC₅₀	6.56 μM Compound: Iproniazid	Inhibition of human recombinant MAOA expressed in baculovirus infected BTI-TN-5B1-4 insect cells assessed as hydrogen peroxide production from p-tyramine after 15 mins by amplex red assay Inhibition of human recombinant MAOA expressed in baculovirus infected BTI-TN-5B1-4 insect cells assessed as hydrogen peroxide production from p-tyramine after 15 mins by amplex red assay	[PMID: 22005185]
BTI-TN-5B1-4	IC₅₀	7.54 μM Compound: Iproniazid	Inhibition of human recombinant MAOB expressed in baculovirus infected BTI-TN-5B1-4 insect cells assessed as hydrogen peroxide production from p-tyramine after 15 mins by amplex red assay Inhibition of human recombinant MAOB expressed in baculovirus infected BTI-TN-5B1-4 insect cells assessed as hydrogen peroxide production from p-tyramine after 15 mins by amplex red assay	[PMID: 22005185]
BTI-TN-5B1-4	IC₅₀	6.56 μM Compound: Iproniazid	Inhibition of human recombinant MAO-A expressed in baculovirus infected BTI-TN-5B1-4 insect cells assessed as inhibition of hydrogen peroxide production from p-tryptamine after 15 mins by fluorimetric method Inhibition of human recombinant MAO-A expressed in baculovirus infected BTI-TN-5B1-4 insect cells assessed as inhibition of hydrogen peroxide production from p-tryptamine after 15 mins by fluorimetric method	[PMID: 22222137]
BTI-TN-5B1-4	IC₅₀	7.54 μM Compound: Iproniazid	Inhibition of human recombinant MAO-B expressed in baculovirus infected BTI-TN-5B1-4 insect cells assessed as inhibition of hydrogen peroxide production from p-tryptamine after 15 mins by fluorimetric method Inhibition of human recombinant MAO-B expressed in baculovirus infected BTI-TN-5B1-4 insect cells assessed as inhibition of hydrogen peroxide production from p-tryptamine after 15 mins by fluorimetric method	[PMID: 22222137]
BTI-TN-5B1-4	IC₅₀	6.56 μM Compound: I	Inhibition of human MAO-A expressed in baculovirus infected BTI-TN-5B1-4 cells using p-tyramine as substrate incubated for 15 mins prior to substrate addition measured for 15 mins by Amplex red assay Inhibition of human MAO-A expressed in baculovirus infected BTI-TN-5B1-4 cells using p-tyramine as substrate incubated for 15 mins prior to substrate addition measured for 15 mins by Amplex red assay	[PMID: 23153812]
BTI-TN-5B1-4	IC₅₀	7.54 μM Compound: I	Inhibition of human MAO-B expressed in baculovirus infected BTI-TN-5B1-4 cells using p-tyramine as substrate incubated for 15 mins prior to substrate addition measured for 15 mins by Amplex red assay Inhibition of human MAO-B expressed in baculovirus infected BTI-TN-5B1-4 cells using p-tyramine as substrate incubated for 15 mins prior to substrate addition measured for 15 mins by Amplex red assay	[PMID: 23153812]
BTI-TN-5B1-4	IC₅₀	6.56 μM Compound: Iproniazid	Inhibition of human recombinant microsomal MAO-A expressed in baculovirus infected BTI-TN-5B1-4 cells using p-tyramine as substrate assessed as production of H2O2 incubated for 15 mins followed by substrate addition measured over 15 mins by fluorimetric a Inhibition of human recombinant microsomal MAO-A expressed in baculovirus infected BTI-TN-5B1-4 cells using p-tyramine as substrate assessed as production of H2O2 incubated for 15 mins followed by substrate addition measured over 15 mins by fluorimetric a	[PMID: 23474901]
BTI-TN-5B1-4	IC₅₀	7.54 μM Compound: Iproniazid	Inhibition of human recombinant microsomal MAO-B expressed in baculovirus infected BTI-TN-5B1-4 cells using p-tyramine as substrate assessed as production of H2O2 incubated for 15 mins followed by substrate addition measured over 15 mins by fluorimetric a Inhibition of human recombinant microsomal MAO-B expressed in baculovirus infected BTI-TN-5B1-4 cells using p-tyramine as substrate assessed as production of H2O2 incubated for 15 mins followed by substrate addition measured over 15 mins by fluorimetric a	[PMID: 23474901]
BTI-TN-5B1-4	IC₅₀	6.56 μM Compound: Iproniazid	Inhibition of human recombinant microsomal MAO-A expressed in baculovirus-infected insect BTI-TN-5B1-4 cells assessed as p-tyramine conversion to H2O2 by fluorescence assay Inhibition of human recombinant microsomal MAO-A expressed in baculovirus-infected insect BTI-TN-5B1-4 cells assessed as p-tyramine conversion to H2O2 by fluorescence assay	[PMID: 23927971]
BTI-TN-5B1-4	IC₅₀	7.54 μM Compound: Iproniazid	Inhibition of human recombinant microsomal MAO-B expressed in baculovirus-infected insect BTI-TN-5B1-4 cells assessed as p-tyramine conversion to H2O2 by fluorescence assay Inhibition of human recombinant microsomal MAO-B expressed in baculovirus-infected insect BTI-TN-5B1-4 cells assessed as p-tyramine conversion to H2O2 by fluorescence assay	[PMID: 23927971]
BTI-TN-5B1-4	IC₅₀	6.56 μM Compound: Iproniazid	Inhibition of human recombinant MAO-A expressed in baculovirus-infected BTI-TN-5B1-4 cell microsomes assessed as decrease in H2O2 production using p-tyramine as substrate preincubated for 15 mins by Amplex Red reagent based fluorimetric method Inhibition of human recombinant MAO-A expressed in baculovirus-infected BTI-TN-5B1-4 cell microsomes assessed as decrease in H2O2 production using p-tyramine as substrate preincubated for 15 mins by Amplex Red reagent based fluorimetric method	[PMID: 24746464]
BTI-TN-5B1-4	IC₅₀	7.54 μM Compound: Iproniazid	Inhibition of human recombinant MAO-B expressed in baculovirus-infected BTI-TN-5B1-4 cell microsomes assessed as decrease in H2O2 production using p-tyramine as substrate preincubated for 15 mins by Amplex Red reagent based fluorimetric method Inhibition of human recombinant MAO-B expressed in baculovirus-infected BTI-TN-5B1-4 cell microsomes assessed as decrease in H2O2 production using p-tyramine as substrate preincubated for 15 mins by Amplex Red reagent based fluorimetric method	[PMID: 24746464]
BTI-TN-5B1-4	IC₅₀	6.56 μM Compound: Iproniazid	Inhibition of human recombinant microsomal MAO-A expressed in baculovirus infected BTI-TN-5B1-4 cells using p-tyramine as substrate assessed as reduction in H2O2 production preincubated for 15 mins followed by substrate addition measured for 15 mins Ample Inhibition of human recombinant microsomal MAO-A expressed in baculovirus infected BTI-TN-5B1-4 cells using p-tyramine as substrate assessed as reduction in H2O2 production preincubated for 15 mins followed by substrate addition measured for 15 mins Ample	[PMID: 27135371]
BTI-TN-5B1-4	IC₅₀	7.54 μM Compound: Iproniazid	Inhibition of human recombinant microsomal MAO-B expressed in baculovirus infected BTI-TN-5B1-4 cells using p-tyramine as substrate assessed as reduction in H2O2 production preincubated for 15 mins followed by substrate addition measured for 15 mins Ample Inhibition of human recombinant microsomal MAO-B expressed in baculovirus infected BTI-TN-5B1-4 cells using p-tyramine as substrate assessed as reduction in H2O2 production preincubated for 15 mins followed by substrate addition measured for 15 mins Ample	[PMID: 27135371]
BTI-TN-5B1-4	IC₅₀	6.56 μM Compound: I	Inhibition of human MAO-A expressed in baculovirus infected BTI-TN-5B1-4 insect cells using p-tyramine as substrate assessed as hydrogen peroxide production by fluorimetric method Inhibition of human MAO-A expressed in baculovirus infected BTI-TN-5B1-4 insect cells using p-tyramine as substrate assessed as hydrogen peroxide production by fluorimetric method	10.1039/C0MD00014K
BTI-TN-5B1-4	IC₅₀	7.54 μM Compound: I	Inhibition of human MAO-B expressed in baculovirus infected BTI-TN-5B1-4 insect cells using p-tyramine as substrate assessed as hydrogen peroxide production by fluorimetric method Inhibition of human MAO-B expressed in baculovirus infected BTI-TN-5B1-4 insect cells using p-tyramine as substrate assessed as hydrogen peroxide production by fluorimetric method	10.1039/C0MD00014K
Sf21	IC₅₀	>1000 μM Compound: Iproniazid	Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake	[PMID: 21965623]
Sf21	IC₅₀	>1000 μM Compound: Iproniazid	Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake	[PMID: 21965623]

In Vitro

Iproniazid (10 mM; 24 h) increases intracellular dopamine content and accelerates DNA fragmentation induced by 0.1 μM Rotenone (HY-B1756) in SH-SY5Y cells^[2].
Iproniazid (100 μM; 10 min) inhibits serotonin metabolism by monoamine oxidase in cultured guinea pig tracheal smooth muscle cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis^[2]

Cell Line:

human dopaminergic SH-SY5Y cells
Concentration:

10 mM
Incubation Time:

24 h
Result:

Increased intracellular dopamine content and accelerated DNA fragmentation induced by 0.1 μM Rotenone, enhancing Rotenone-induced apoptosis.

In Vivo

Iproniazid (100 mg/kg; i.p.; 150 min before Lidocaine administration) lowers the median convulsant dose of Lidocaine in mice, reducing the seizure threshold ^[4].
Iproniazid (i.p.) causes hepatic necrosis in Sprague-Dawley and Fischer rats^[5].
Iproniazid dihydrochloride (53-224 mg/kg; p.o.; daily) retards sexual maturation, lengthens the estrous cycle, and inhibits corpus luteum formation in female rats^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

female rats (e.g., initial weight 106-130 g, age 35-45 days) ^[6]
Dosage:

53, 200, 205, 224 mg/kg
Administration:

oral, daily, 30, 40, 61, 67 days
Result:

Retarded sexual maturation (delayed vagina patency), lengthened estrous cycle.
Inhibited corpus luteum formation, caused hypotrophy of ovarian interstitial tissue and retarded uterine development.

Chemical Information

CAS No. 54-92-2
Appearance Solid
Molecular Weight 179.22
Formula C₉H₁₃N₃O
Color White to off-white
SMILES

O=C(C1=CC=NC=C1)NNC(C)C
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Publications (2)

All

Sort by:

Journal Impact Factor

Nat Commun

Palmitoyltransferase DHHC9 and acyl protein thioesterase APT1 modulate renal fibrosis through regulating β-catenin palmitoylation. [Abstract]

2023 Oct 21;14(1):6682. PMID: 37865665
Biotechnol Bioeng

An integrated biomimetic array chip for establishment of collagen-based 3D primary human hepatocyte model for prediction of clinical drug-induced liver injury. [Abstract]

2021 Dec;118(12):4687-4698. PMID: 34478150

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (557.97 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : ≥ 100 mg/mL (557.97 mM)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

5.5797 mL

27.8987 mL

55.7973 mL

5 mM

1.1159 mL

5.5797 mL

11.1595 mL

10 mM

0.5580 mL

2.7899 mL

5.5797 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (13.95 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (13.95 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (13.95 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Fagervall I, et al. Inhibition of monoamine oxidase in monoaminergic neurones in the rat brain by irreversible inhibitors. Biochemical pharmacology 35 (8): 1381–1387

[2]. Watabe M, et al. Mitochondrial complex I inhibitor rotenone-elicited dopamine redistribution from vesicles to cytosol in human dopaminergic SH-SY5Y cells. J Pharmacol Exp Ther. 2007 Nov;323(2):499-507. [Content Brief]

[3]. Dodson AM, et al. Serotonin uptake and metabolism by cultured guinea pig airway smooth muscle cells. Pulm Pharmacol Ther. 2004;17(1):19-25. [Content Brief]

[4]. De Oliveira LF, et al. Effects of 5-hydroxytryptophan, iproniazid and p-chlorophenylalanine on lidocaine seizure threshold of mice. Eur J Pharmacol. 1974 Nov;29(1):5-9. [Content Brief]

[5]. Nelson SD, et al. Hepatotoxicity and metabolism of iproniazid and isopropylhydrazine. J Pharmacol Exp Ther. 1978 Sep;206(3):574-85. [Content Brief]

[6]. SETNIKAR I V O, et al. Retardation of sexual development in female rats due to iproniazid treatment. Endocrinology, 1960, 67(4): 511-520.

[7]. Huang J T, et al. The effect of pretreatment with iproniazid on the behavioral activities of β-phenylethylamine in rats. Psychopharmacologia, 1974, 35(1): 77-81.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO / H₂O	1 mM	5.5797 mL	27.8987 mL	55.7973 mL	139.4934 mL
	5 mM	1.1159 mL	5.5797 mL	11.1595 mL	27.8987 mL
	10 mM	0.5580 mL	2.7899 mL	5.5797 mL	13.9493 mL
	15 mM	0.3720 mL	1.8599 mL	3.7198 mL	9.2996 mL
	20 mM	0.2790 mL	1.3949 mL	2.7899 mL	6.9747 mL
	25 mM	0.2232 mL	1.1159 mL	2.2319 mL	5.5797 mL
	30 mM	0.1860 mL	0.9300 mL	1.8599 mL	4.6498 mL
	40 mM	0.1395 mL	0.6975 mL	1.3949 mL	3.4873 mL
	50 mM	0.1116 mL	0.5580 mL	1.1159 mL	2.7899 mL
	60 mM	0.0930 mL	0.4650 mL	0.9300 mL	2.3249 mL
	80 mM	0.0697 mL	0.3487 mL	0.6975 mL	1.7437 mL
	100 mM	0.0558 mL	0.2790 mL	0.5580 mL	1.3949 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Iproniazid

Apoptosis Compound Library

Neuronal Signaling Compound Library

FDA-Approved Drug Library

Drug Repurposing Compound Library

Reprogramming Compound Library

Endocrinology Compound Library

FDA Approved & Pharmacopeial Drug Library

Drug-Induced Liver Injury (DILI) Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Mitochondria-Targeted Compound Library

Rare Diseases Drug Library

Antidepressant Compound Library

Human Metabolite Library

Heterocyclic Compound Library

Withdrawn Drug Compound Library

Off-patent Drug Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

MCE Kinase Hinge Binder Fragment Library

Publications Citing Use of MedChemExpress (MCE) Iproniazid

All Monoamine Oxidase Isoforms

Biological Activity

Chemical Information

Publications (2)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Iproniazid Related Classifications

HY-B0886A Related Classifications